ArQule (ARQL) dives 64% premarket following the discontinuation of its Phase 3 MARQUEE (c-Met...

|By:, SA News Editor

ArQule (ARQL) dives 64% premarket following the discontinuation of its Phase 3 MARQUEE (c-Met inhibitor ARQ 197) trial. "We are disappointed that the MARQUEE trial did not provide statistically significant results." (PR)